Evidence map›Paper›PMID 32455534›Full record

ArticleInternational journal of molecular sciences2020

Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.

André Fischer, Manuel Sellner, Santhosh Neranjan, Martin Smieško, Markus A Lill

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
    Article
  14. Progress of the "Molecular Informatics" Section in 2022.International journal of molecular sciences · 2023
    Article
  15. Article
  16. Frontiers in pharmacology · 2023
    Article
  17. Solubility Enhancement of Dihydroquercetin via "Green" Phase Modification.International journal of molecular sciences · 2022
    Article
  18. Paving New Roads UsingIranian journal of pharmaceutical research : IJPR · 2022
    Review
  19. Article
  20. AnJournal of biomolecular structure & dynamics · 2022
    Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

André FischerComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-6386-2324
Manuel SellnerComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-3961-0175
Santhosh NeranjanComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-2944-652X
Martin SmieškoComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-2758-2680
Markus A LillComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-3023-5188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China followed by its spread around the world poses a serious global concern for public health. To this date, no specific drugs or vaccines are available to treat SARS-CoV-2 despite its close relation to the SARS-CoV virus that caused a similar epidemic in 2003. Thus, there remains an urgent need for the identification and development of specific antiviral therapeutics against SARS-CoV-2. To conquer viral infections, the inhibition of proteases essential for proteolytic processing of viral polyproteins is a conventional therapeutic strategy. In order to find novel inhibitors, we computationally screened a compound library of over 606 million compounds for binding at the recently solved crystal structure of the main protease (M

Indexed as

Binding SitesComputer SimulationCoronavirus 3C ProteasesCoronavirus InfectionsCOVID-19Cysteine EndopeptidasesDrug DiscoveryMolecular Docking SimulationPandemicsPneumonia, ViralProtease InhibitorsProtein BindingSmall Molecule LibrariesViral Nonstructural ProteinsCoronavirus 3C ProteasesCysteine EndopeptidasesProtease InhibitorsSmall Molecule LibrariesViral Nonstructural Proteinscomputational chemistrycoronavirusSARS-2-CoVvirtual screening

Identifiers

PMID32455534
PMCPMC7279339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.